Enter to submit · Shift+Enter for new line · AI routes your input automatically
Good evening
Enter to submit · Shift+Enter for new line · AI routes your input automatically
My deep dive into your lab results over time
Kidney function has been consistently normal throughout the entire tracking period — eGFR, creatinine, and BUN have all remained stable and reassuring
CBC has been remarkably stable across all draws — no anemia, no concerning white cell patterns, and platelets have been consistently normal
Thyroid function (when checked) has been normal, ruling out thyroid dysfunction as a contributor to metabolic symptoms
PSA has been normal on checks, which is reassuring for a man on TRT
START LIPID-LOWERING THERAPY NOW
RoutineEight years of documented, significantly elevated LDL (123–192 mg/dL) with a mixed hyperlipidemia diagnosis and zero evidence of statin or other lipid-lowering medication is the most critical gap in your care. With your cardiovascular risk profile (metabolic syndrome, hypertension, obesity), your LDL goal should be well below 100 — ideally below 70. This conversation cannot wait for another visit.
GET A COMPREHENSIVE METABOLIC WORKUP
RoutineYou need fasting insulin, HbA1c, and a HOMA-IR calculation at your next draw. The pattern of rising glucose (now 102 despite tirzepatide), low HDL, high triglycerides, central obesity, and blood pressure 129/90 strongly suggests insulin resistance or prediabetes that has never been formally diagnosed. You can't treat what you haven't measured.
OPTIMIZE YOUR TRT PROTOCOL AND MONITOR HEMATOCRIT CLOSELY
RoutineYour testosterone levels have been wildly variable — from 108 to 1412 across different draws. The early 2025 result (total T 387, free T 6.5 below range on 200mg/week) suggests timing, absorption, or compliance issues. Meanwhile, hematocrit at 51.3% is trending toward the 54% intervention line. You need consistent lab timing (trough levels drawn the day before your next injection), hematocrit checked every 3-4 months, and a plan in place for if it crosses 54%.
Chronically elevated LDL cholesterol — flagged high on every lipid panel from 2017 through 2025, ranging from 123 to 192 mg/dL, with no evidence of lipid-lowering pharmacotherapy
Persistently low HDL cholesterol — ranging from 33 to 51 mg/dL across all draws, providing inadequate cardiovascular protection especially against the elevated LDL
Mixed hyperlipidemia diagnosis present since at least 2017 with no apparent pharmacological management across eight years of data
Your health story begins in 2016 with confirmed hypogonadism — a total testosterone of 306, below the lab's reference floor — and no lipid or metabolic baseline to work from. By late 2017, your first lipid panel revealed the beginning of what would become a persistent, defining pattern: LDL at 154, total cholesterol at 223, both significantly elevated. Over the next seven years, every single lipid panel told the same story, often getting worse: LDL peaked at 192 in early 2021, total cholesterol hit 267, triglycerides reached 234, and HDL dropped as low as 33. Not once across any period does the data suggest active lipid-lowering medication was in use. Meanwhile, your testosterone journey has been turbulent — from the initial low of 306, to an unexplained catastrophic drop to 108 in late 2022 (with estradiol bottoming out alongside it), to therapeutic TRT levels reaching 995–1412 when the protocol is working. But even on TRT, there have been periods of apparent underperformance (387 total T and below-range free T at 6.5 in early 2025), suggesting protocol inconsistency or timing issues. TRT has brought expected side effects: hematocrit has been climbing and reached 51.3% in the most recent draw, only 2.7 points from the intervention threshold. Liver enzymes have spiked intermittently — AST hit 151 in 2018, ALT reached 107 in early 2021 and 79 in late 2022 — though they've normalized between episodes. Fasting glucose has been gradually drifting upward, reaching 102 (impaired fasting glucose territory) in early 2025 despite being on tirzepatide, which should be pushing glucose down. Vitamin D recovered from deficiency (22.9 in early 2021) to excellent levels (90.7 in early 2025), though it dropped back to 36 by late 2025, suggesting supplementation may have been interrupted or is underdosed. Throughout all of this, there have been significant gaps in monitoring — multiple periods with no lipid panel despite active hyperlipidemia, no testosterone levels during key windows, and no A1C or insulin testing to characterize the metabolic syndrome pattern that these labs strongly suggest.
Curious about something in your results? I have your full history right here — just ask.